Sandoz Defeat On Amgen’s Otezla Pushes US Generic Opportunity Back To 2028
Zydus Cadila Also On Receiving End Of Unfavorable Ruling
Amgen is set to enjoy its monopoly on the Otezla oral treatment for plaque psoriasis until late into the decade, after ANDA sponsors Sandoz and Zydus Cadila failed to find a way around the originator’s intellectual property, including a key patent expiring early in 2028.
